Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of ProAgio in Advanced Pancreatic Cancer and Solid Tumors
NCT05085548Phase 1Completed
- Sponsor
- ProDa BioTech
- Start
- Oct 2021
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, PEGylated Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of proagio in pancreatic cancer (PC) and solid tumor (3 arms), sponsored by ProDa BioTech. Primary endpoint: Recommended Phase 2 Dose at 3 years. Started Oct 2021; status: completed.
02
Drugs
proagio
03
Conditions
pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT05085548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085548.